$SAGE
Sage Therapeutics, Inc.

2017 Q4 Form 10-Q Financial Statement

#000156459017020982 Filed on November 02, 2017

View on sec.gov

Income Statement

Concept 2017 Q4 2017 Q3 2016 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $19.60M $16.10M $14.40M
YoY Change 36.11% 78.89% 75.61%
% of Gross Profit
Research & Development $50.90M $58.29M $42.00M
YoY Change 21.19% 100.47% 105.88%
% of Gross Profit
Depreciation & Amortization $100.0K $100.0K $100.0K
YoY Change 0.0% 0.0%
% of Gross Profit
Operating Expenses $70.45M $74.37M $56.38M
YoY Change 24.95% 95.39% 97.05%
Operating Profit -$70.45M -$74.37M -$56.38M
YoY Change 24.95% 95.39% 97.05%
Interest Expense $1.000M $677.0K $500.0K
YoY Change 100.0% 146.18% 400.0%
% of Operating Profit
Other Income/Expense, Net $0.00 -$23.00K $0.00
YoY Change 228.57%
Pretax Income -$69.40M -$73.70M -$55.90M
YoY Change 24.15% 94.97% 95.45%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$69.42M -$73.72M -$55.90M
YoY Change 24.19% 95.04% 95.72%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$1.718M -$1.965M -$1.499M
COMMON SHARES
Basic Shares Outstanding 37.54M 37.47M 37.17M
Diluted Shares Outstanding 37.47M

Balance Sheet

Concept 2017 Q4 2017 Q3 2016 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $518.8M $243.5M $397.5M
YoY Change 30.53% -43.55% 112.78%
Cash & Equivalents $306.2M $134.9M $168.5M
Short-Term Investments $212.6M $108.5M $229.0M
Other Short-Term Assets $6.200M $4.900M $5.100M
YoY Change 21.57% 44.12% 200.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $525.1M $248.3M $402.6M
YoY Change 30.43% -42.87% 113.58%
LONG-TERM ASSETS
Property, Plant & Equipment $4.013M $1.893M $1.388M
YoY Change 189.12% 89.3% 385.31%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $800.0K $800.0K $600.0K
YoY Change 33.33% 33.33% 200.0%
Total Long-Term Assets $4.862M $2.742M $1.952M
YoY Change 149.08% 71.38% 271.81%
TOTAL ASSETS
Total Short-Term Assets $525.1M $248.3M $402.6M
Total Long-Term Assets $4.862M $2.742M $1.952M
Total Assets $529.9M $251.1M $404.5M
YoY Change 31.0% -42.45% 114.02%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $9.350M $13.03M $12.82M
YoY Change -27.05% 150.58% 148.44%
Accrued Expenses $42.60M $36.81M $22.35M
YoY Change 90.59% 1126.9% 120.26%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $51.95M $49.84M $35.17M
YoY Change 47.72% 123.48% 129.76%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $2.511M $1.196M $845.0K
YoY Change 197.16% 498.0% 5935.71%
Total Long-Term Liabilities $2.511M $1.196M $845.0K
YoY Change 197.16% 498.0% 5935.71%
TOTAL LIABILITIES
Total Short-Term Liabilities $51.95M $49.84M $35.17M
Total Long-Term Liabilities $2.511M $1.196M $845.0K
Total Liabilities $54.46M $51.03M $36.01M
YoY Change 51.22% 125.81% 135.06%
SHAREHOLDERS EQUITY
Retained Earnings -$590.4M -$320.3M
YoY Change 84.33% 98.54%
Common Stock $1.066B $4.000K $689.0M
YoY Change 54.73% -100.0% 105.64%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $475.5M $200.1M $368.5M
YoY Change
Total Liabilities & Shareholders Equity $529.9M $251.1M $404.5M
YoY Change 31.0% -42.45% 114.02%

Cashflow Statement

Concept 2017 Q4 2017 Q3 2016 Q4
OPERATING ACTIVITIES
Net Income -$69.42M -$73.72M -$55.90M
YoY Change 24.19% 95.04% 95.72%
Depreciation, Depletion And Amortization $100.0K $100.0K $100.0K
YoY Change 0.0% 0.0%
Cash From Operating Activities -$58.90M -$46.10M -$33.80M
YoY Change 74.26% 49.68% 86.74%
INVESTING ACTIVITIES
Capital Expenditures -$800.0K -$300.0K -$500.0K
YoY Change 60.0% 200.0%
Acquisitions
YoY Change
Other Investing Activities -$103.8M $44.10M -$117.4M
YoY Change -11.58% -259.21%
Cash From Investing Activities -$104.6M $43.90M -$117.9M
YoY Change -11.28% -258.48%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 334.8M 3.700M 700.0K
YoY Change 47728.57% -98.05% 600.0%
NET CHANGE
Cash From Operating Activities -58.90M -46.10M -33.80M
Cash From Investing Activities -104.6M 43.90M -117.9M
Cash From Financing Activities 334.8M 3.700M 700.0K
Net Change In Cash 171.3M 1.500M -151.0M
YoY Change -213.44% -98.86% 738.89%
FREE CASH FLOW
Cash From Operating Activities -$58.90M -$46.10M -$33.80M
Capital Expenditures -$800.0K -$300.0K -$500.0K
Free Cash Flow -$58.10M -$45.80M -$33.30M
YoY Change 74.47% 49.19% 83.98%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
168517000
CY2017Q3 us-gaap Assets
Assets
251085000
CY2017Q3 us-gaap Assets Current
AssetsCurrent
248343000
CY2017Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
13030000
CY2017Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
36807000
CY2017Q3 us-gaap Liabilities Current
LiabilitiesCurrent
49837000
CY2017Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1196000
CY2017Q3 us-gaap Liabilities
Liabilities
51033000
CY2017Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2017Q3 us-gaap Common Stock Value
CommonStockValue
4000
CY2017Q3 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
17000
CY2017Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
849000
CY2017Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1893000
CY2016Q4 us-gaap Liabilities
Liabilities
36014000
CY2016Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
228962000
CY2016Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-102000
CY2016Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2016Q4 us-gaap Assets Current
AssetsCurrent
402579000
CY2017Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
37537655
CY2017Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
108535000
CY2016Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2016Q4 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
17000
CY2017Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4892000
CY2016Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5100000
CY2016Q4 us-gaap Liabilities Current
LiabilitiesCurrent
35169000
CY2017Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
134916000
CY2016Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
688959000
CY2016Q4 us-gaap Common Stock Value
CommonStockValue
4000
CY2016Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
12817000
CY2016Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
564000
CY2016Q4 us-gaap Assets
Assets
404531000
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
404531000
CY2016Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
845000
CY2016Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
22352000
CY2016Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2016Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1388000
CY2017Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-15000
CY2017Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-33601000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
133325000
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
186753000
CY2016Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
320078000
sage Capital Expenditures Incurred Financed By Landlord Tenant Incentive But Not Yet Paid
CapitalExpendituresIncurredFinancedByLandlordTenantIncentiveButNotYetPaid
353000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
106000
us-gaap Nature Of Operations
NatureOfOperations
<div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1. Nature of Operations</p> <p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Sage Therapeutics, Inc. (&#8220;Sage&#8221; or the &#8220;Company&#8221;) is a clinical-stage biopharmaceutical company committed to developing and commercializing novel medicines to treat life-altering central nervous system, or CNS, disorders, where there are no approved therapies or existing therapies are inadequate.&nbsp;&nbsp;The Company has a portfolio of product candidates with a current focus on modulating two critical CNS receptor systems, GABA and NMDA.&nbsp;&nbsp;The GABA receptor family, which is recognized as the major inhibitory neurotransmitter in the CNS, mediates downstream neurologic and bodily function via activation of GABA<sub style="font-size:85%; vertical-align:bottom">A</sub> receptors.&nbsp;&nbsp;The NMDA-type receptors of the glutamate receptor system are a major excitatory receptor system in the CNS.&nbsp;&nbsp;Dysfunction in these systems is implicated in a broad range of CNS disorders.&nbsp;&nbsp;The Company is targeting CNS indications where patient populations are easily identified, clinical endpoints are well-defined, and development pathways are feasible.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company was incorporated under the laws of the State of Delaware on April&#160;16, 2010, and commenced operations on January&#160;19, 2011 as Sterogen Biopharma, Inc. On September&#160;13, 2011, the Company changed its name to Sage Therapeutics, Inc.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is subject to risks and uncertainties common to companies in the biotech industry, including, but not limited to, the risks associated with developing product candidates at each stage of non-clinical and clinical development; the challenges associated with gaining regulatory approval of such product candidates; the risks associated with commercializing pharmaceutical products, if approved for marketing and sale; the potential for development by third parties of new technological innovations that may compete with the Company&#8217;s products; the dependence on key personnel; the challenges of protecting proprietary technology; the need to comply with government regulations; the high costs of drug development; and the uncertainty of being able to secure additional capital when needed to fund operations.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has incurred losses and negative cash flows from operations since its inception. As of September&#160;30, 2017, the Company had an accumulated deficit of $521.0&#160;million. From its inception through September&#160;30, 2017, the Company received net proceeds of $643.3 million from the sales of redeemable convertible preferred stock, the issuance of convertible notes, and the proceeds from its initial public offering (&#8220;IPO&#8221;) in July 2014 and follow-on underwritten public offerings in April 2015, January 2016 and September 2016. <font style="letter-spacing:-0.1pt;">Until such time, if ever, as the Company can generate substantial product revenue, the Company expects to finance its cash needs through a combination of equity offerings, debt financings, collaborations, strategic alliances, licensing arrangements and other sources of funding.&nbsp;&nbsp;If the Company is unable to raise additional funds through equity or debt financings when needed, the Company may be required to delay, limit, reduce or terminate product development or future commercialization efforts or grant rights to develop and market products or product candidates that the Company would otherwise prefer to develop and market itself.</font></p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based on its current operating plans, the Company believes its cash, cash equivalents and marketable securities of $243.5&#160;million as of September&#160;30, 2017 will be sufficient to fund its anticipated level of operations and capital expenditures into the second quarter of 2018.</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under Accounting Standards Update, or ASU, 2014-15, <font style="font-style:italic;">Presentation of Financial Statements&#8212;Going Concern</font> (Subtopic 205-40), or ASC 205-40, the Company has the responsibility to evaluate whether conditions and/or events raise substantial doubt about its ability to meet its future financial obligations as they become due within one year after the date that the financial statements are issued. As required by ASC 205-40, this evaluation shall initially not take into consideration the potential mitigating effects of plans that have not been fully implemented as of the date the financial statements are issued.<font style="color:#000000;">&#160;&#160;</font></p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company anticipates that its current capital resources will enable it to meet its anticipated operational expenses and capital expenditures into the second quarter of calendar year 2018<font style="color:#000000;">. As of September&#160;30, 2017, management has assessed the Company&#8217;s ability to continue as a going concern in accordance with the requirements of ASC 205-40.&nbsp;&nbsp;Management has determined that the Company&#8217;s accumulated deficit, history of losses, and future expected losses meet the ASC 205-40 standard for raising substantial doubt about the Company&#8217;s ability to continue as a going concern within one year of the issuance date of these condensed consolidated financial statements. As of September&#160;30, 2017, the Company had an accumulated deficit of $521.0 million and cash, cash equivalents and short-term investments on hand of $243.5 million. The Company is currently forecasting a significant increase in expenditures to support a </font><font style="Background-color:#FFFFFF;">potential filing of a New Drug Application, or NDA, for brexanolone in postpartum depression, or PPD, in the U.S. and future potential regulatory filings in the European Union, or EU</font><font style="color:#000000;">, if the results of the Phase 3 clinical trials in PPD are positive and support such filings, continued</font><font style="Background-color:#FFFFFF;"> preparations for a potential future commercial launch of brexanolone, if successfully developed and approved, and spending on other clinical programs in development. The Company&#8217;s current financial resources would not be sufficient to fund the Company&#8217;s currently forecasted operating plan for a one year period from the issuance of these condensed consolidated financial statements.&nbsp;&nbsp;</font><font style="color:#000000;">The Company has developed plans to mitigate this risk, which primarily consist of raising additional capital through a combination of equity or debt financings, and, depending on the availability and level of additional financings, potentially new collaborations and reducing cash expenditures.</font></p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company currently expects to seek additional funding. While the Company has raised capital in the past, the ability to raise capital in future periods is not considered probable, as defined under the accounting standards. As such, under the requirements of ASC 205-40, management may not consider the potential for future capital raises in their assessment of the Company&#8217;s ability to meet its obligations for the next 12 months.</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the Company is not able to secure adequate additional funding, the Company plans to make reductions in spending. In that event, the Company may have to delay, reduce the scope of, suspend or eliminate one or more research and development programs or reduce spending and hiring in connection with the Company&#8217;s commercialization efforts. The actions necessary to reduce spending under this plan at a level that mitigates the factors described above is not considered probable, as defined in the accounting standards; as such, under the requirements of ASC 205-40, the full extent to which management may extend the Company&#8217;s funds through these actions may not be considered in management&#8217;s assessment of the Company&#8217;s ability to continue as a going concern for the next 12 months as defined by ASC 205-40.</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a result, in accordance with the requirements of ASC 205-40, management has concluded that it is required to disclose that substantial doubt exists about the Company&#8217;s ability to continue as a going concern for one year from the date these financial statements are issued. While management has plans in place to mitigate these actions, they are not considered probable, as defined in the accounting standards, and a failure to raise the additional funding or to effectively implement cost reductions could harm the Company&#8217;s business, results of operations and future prospects.</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying unaudited interim condensed consolidated financial statements of the Company have been prepared on a going-concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The accompanying unaudited interim condensed consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from uncertainty related to the ability to continue as a going concern.</p></div>
CY2017Q3 us-gaap Stockholders Equity
StockholdersEquity
200052000
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
37222172
sage Premium On Marketable Securities
PremiumOnMarketableSecurities
663000
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
57000
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
-87000
us-gaap Depreciation
Depreciation
199000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1680000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
116000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
7198000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-84902000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
214436000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
7999000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
93816000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
118650000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
556000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
901000
us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
285000
us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
525000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
119779000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-112077000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
6998000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
728000
us-gaap Payment Of Financing And Stock Issuance Costs
PaymentOfFinancingAndStockIssuanceCosts
599000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
330175000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
6998000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
330304000
CY2016Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2016Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
346
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
37222518
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-35000
CY2016Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-74000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
87000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-35000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
87000
CY2017Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-23000
us-gaap Operating Expenses
OperatingExpenses
202706000
CY2017Q3 us-gaap Operating Expenses
OperatingExpenses
74373000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
717000
CY2017Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
58286000
CY2017Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
16087000
CY2017Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2016Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-38064000
CY2016Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
29075000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
25033000
us-gaap Operating Income Loss
OperatingIncomeLoss
-103785000
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-320327000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
159386000
us-gaap Operating Expenses
OperatingExpenses
103785000
CY2016Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-7000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
78752000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-48000
CY2016Q3 us-gaap Net Income Loss
NetIncomeLoss
-37796000
CY2017Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-74373000
us-gaap Operating Income Loss
OperatingIncomeLoss
-202706000
CY2016Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
275000
CY2016Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8989000
CY2016Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.15
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-5.37
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-3.20
CY2017Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
43320000
CY2016Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
32975897
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
37367802
CY2017Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
677000
CY2017Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
37524984
CY2017Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
37524638
CY2017Q3 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
346
CY2016Q3 us-gaap Operating Expenses
OperatingExpenses
38064000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
2056000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-18000
CY2017Q3 us-gaap Net Income Loss
NetIncomeLoss
-73719000
us-gaap Net Income Loss
NetIncomeLoss
-200698000
us-gaap Net Income Loss
NetIncomeLoss
-103086000
CY2017Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.97
CY2017Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
37470912
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
32218204
CY2017Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
52000
CY2016Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-74000
CY2017Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
52000
CY2017Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-73667000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-103121000
us-gaap Share Based Compensation
ShareBasedCompensation
25289000
CY2016Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-37870000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-200611000
us-gaap Share Based Compensation
ShareBasedCompensation
12927000
sage Premium On Marketable Securities
PremiumOnMarketableSecurities
49000
us-gaap Depreciation
Depreciation
396000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-208000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
221000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
14312000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-160378000
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
368517000
CY2017Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
251085000
CY2017Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2016Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2017Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2016Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2017Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2016Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
3157894
CY2016Q1 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
47.50
CY2016Q1 sage Proceeds From Issuance Of Common Stock Net Of Offering Expenses
ProceedsFromIssuanceOfCommonStockNetOfOfferingExpenses
140400000
CY2017Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37470912
CY2017Q3 us-gaap Incremental Common Shares Attributable To Conversion Of Preferred Stock
IncrementalCommonSharesAttributableToConversionOfPreferredStock
0
CY2017Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37470912
CY2017Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5296525
CY2017Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
16000
CY2017Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
108535000
CY2017Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
243451000
CY2016Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
168517000
CY2016Q4 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
228962000
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p></div>
CY2017Q3 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
108535000
CY2017Q3 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
134916000
CY2017Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
243500000
CY2016Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
397479000
CY2017Q3 sage Fair Value Assets Transfers Among Level1 Level2 And Level3 Amount
FairValueAssetsTransfersAmongLevel1Level2AndLevel3Amount
0
CY2016Q3 sage Fair Value Assets Transfers Among Level1 Level2 And Level3 Amount
FairValueAssetsTransfersAmongLevel1Level2AndLevel3Amount
0
CY2017Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
108550000
CY2017Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
1000
CY2016Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
229064000
CY2016Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
2000
CY2016Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
104000
CY2016Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
228962000
CY2017Q3 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2016 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2017Q3 sage Accrued Development Expenses Current
AccruedDevelopmentExpensesCurrent
27326000
CY2016Q4 sage Accrued Development Expenses Current
AccruedDevelopmentExpensesCurrent
14541000
CY2017Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
6299000
CY2016Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
5948000
CY2017Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
3179000
CY2016Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1751000
CY2017Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
3000
CY2016Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
112000
CY2017Q3 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
782000
CY2017Q3 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
4444000
CY2017Q3 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
4537000
CY2017Q3 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
4632000
CY2017Q3 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
4728000
CY2017Q3 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
8935000
CY2017Q3 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
28058000
CY2016Q3 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
5062892
CY2016Q3 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
39.75
CY2016Q3 sage Proceeds From Issuance Of Common Stock Net Of Offering Expenses
ProceedsFromIssuanceOfCommonStockNetOfOfferingExpenses
189200000
CY2017Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9731000
CY2016Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4748000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
25289000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
12927000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
40.43
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
23.32
CY2016Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
32975897
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37367802
CY2016Q3 us-gaap Incremental Common Shares Attributable To Conversion Of Preferred Stock
IncrementalCommonSharesAttributableToConversionOfPreferredStock
0
us-gaap Incremental Common Shares Attributable To Conversion Of Preferred Stock
IncrementalCommonSharesAttributableToConversionOfPreferredStock
0
us-gaap Incremental Common Shares Attributable To Conversion Of Preferred Stock
IncrementalCommonSharesAttributableToConversionOfPreferredStock
0
CY2016Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
32975897
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37367802
CY2016Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3638146
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5296525
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3638146

Files In Submission

Name View Source Status
0001564590-17-020982-index-headers.html Edgar Link pending
0001564590-17-020982-index.html Edgar Link pending
0001564590-17-020982.txt Edgar Link pending
0001564590-17-020982-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g2017110119155784913943.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
sage-10q_20170930.htm Edgar Link pending
sage-20170930.xml Edgar Link completed
sage-20170930.xsd Edgar Link pending
sage-20170930_cal.xml Edgar Link unprocessable
sage-20170930_def.xml Edgar Link unprocessable
sage-20170930_lab.xml Edgar Link unprocessable
sage-20170930_pre.xml Edgar Link unprocessable
sage-ex101_169.htm Edgar Link pending
sage-ex311_7.htm Edgar Link pending
sage-ex312_9.htm Edgar Link pending
sage-ex321_10.htm Edgar Link pending
Show.js Edgar Link pending